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Artificial intelligence framework identifies
candidate targets for drug repurposing
in Alzheimer’s disease
Jiansong Fang1†, Pengyue Zhang2†, Quan Wang3,4†, Chien‑Wei Chiang5, Yadi Zhou1, Yuan Hou1, Jielin Xu1,
Rui Chen3,4, Bin Zhang1, Stephen J. Lewis6, James B. Leverenz7,8, Andrew A. Pieper9,10,11,12,13, Bingshan Li3,4*,
Lang Li5*, Jeffrey Cummings14 and Feixiong Cheng1,7,15*

Abstract
Background: Genome-wide association studies (GWAS) have identified numerous susceptibility loci for Alzheimer’s
disease (AD). However, utilizing GWAS and multi-omics data to identify high-confidence AD risk genes (ARGs) and
druggable targets that can guide development of new therapeutics for patients suffering from AD has heretofore not
been successful.
Methods: To address this critical problem in the field, we have developed a network-based artificial intelligence
framework that is capable of integrating multi-omics data along with human protein–protein interactome networks
to accurately infer accurate drug targets impacted by GWAS-identified variants to identify new therapeutics. When
applied to AD, this approach integrates GWAS findings, multi-omics data from brain samples of AD patients and AD
transgenic animal models, drug-target networks, and the human protein–protein interactome, along with large-scale
patient database validation and in vitro mechanistic observations in human microglia cells.
Results: Through this approach, we identified 103 ARGs validated by various levels of pathobiological evidence in
AD. Via network-based prediction and population-based validation, we then showed that three drugs (pioglitazone,
febuxostat, and atenolol) are significantly associated with decreased risk of AD compared with matched control
populations. Pioglitazone usage is significantly associated with decreased risk of AD (hazard ratio (HR) = 0.916, 95%
confidence interval [CI] 0.861–0.974, P = 0.005) in a retrospective case-control validation. Pioglitazone is a peroxisome
proliferator-activated receptor (PPAR) agonist used to treat type 2 diabetes, and propensity score matching cohort
studies confirmed its association with reduced risk of AD in comparison to glipizide (HR = 0.921, 95% CI 0.862–0.984,
P = 0.0159), an insulin secretagogue that is also used to treat type 2 diabetes. In vitro experiments showed that
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pioglitazone downregulated glycogen synthase kinase 3 beta (GSK3β) and cyclin-dependent kinase (CDK5) in human
microglia cells, supporting a possible mechanism-of-action for its beneficial effect in AD.
Conclusions: In summary, we present an integrated, network-based artificial intelligence methodology to rapidly
translate GWAS findings and multi-omics data to genotype-informed therapeutic discovery in AD.
Keywords: Alzheimer’s disease, Drug repurposing, Genome-wide association studies (GWAS), Multi-omics, Network
medicine, Pioglitazone

Background
Alzheimer’s disease (AD) is a chronic neurodegenerative
disorder associated with progressive cognitive decline,
extracellular amyloid plaques, intracellular neurofibrillary
tangles, and neuronal death [1, 2]. AD and other dementias are an increasingly important global health burden,
recently estimated to affect 43.8 million people worldwide
[3]. Although genome-wide association studies (GWAS)
have identified over 40 genome-wide significant susceptibility loci for AD [4–7], translating these findings into
identification of high-confidence AD risk genes (ARGs)
and potential therapies has eluded the field. Indeed, since
Dr. Alois Alzheimer first described the condition in 1906,
there are only five small-molecule drugs approved by the
U.S. Food and Drug Administration (FDA) for treatment
of AD: three cholinesterase inhibitors (donepezil, galantamine, and rivastigmine), one N-methyl-D-aspartate
(NMDA) receptor antagonist (memantine), and one fixed
combination of donepezil and memantine [8]. Aducanumab, a monoclonal antibody targeting aggregated betaamyloid, is the first disease-modifying drug approved by
U.S FDA for Alzheimer’s treatment in nearly 20 years; yet,
its clinical efficacy is limited to a narrow segment of the
AD continuum andpotential side effects [1, 9].
The number of AD patients is expected to rise to 13.8
million by 2050 in the United States (U.S.) alone [10, 11],
while the attrition rate for AD clinical trials (2002–2012)
is estimated at 99.6% [12]. One possible explanation for
why most candidate drugs fail in later-stage clinical trials is poor target selection. Broadly in disease, drug targets with genetic support have carried a high success
rate among U.S. Food and Drug Administration (FDA)approved therapies [13, 14]. However, this has not been
the case with AD, and the translational application of
multi-omics data such as GWAS for target identification
and therapeutic development in AD remains challenging.
We recently demonstrated the utility of network-based
methodologies for accelerating target identification and
therapeutic discovery by exploiting multi-omics profiles
from individual patients in multiple complex diseases,
including cardiovascular disease [15], cancer [16], schizophrenia [17], and AD [18, 19]. We now posit that systematic identification of likely causal genes by incorporating
GWAS findings and multi-omics profiles with human

interactome network models will also reveal diseasespecific targets for genotype-informed therapeutic discovery in AD. This approach entails unique integration
of the genome, transcriptome, proteome, and the human
protein–protein interactome. In this study, we presented
a network-based artificial intelligence (AI) framework
that is capable of integrating multi-omics data along with
human protein–protein interactome networks to accurately infer drug targets impacted by GWAS-identified
variants to identify new therapeutics. Specifically, under
the AI framework, we first apply a Bayesian algorithm
to infer AD risk genes (termed ARGs) from AD GWAS
loci via integrating multi-omics data and gene networks.
Then repurposable drugs will be prioritized by quantifying the network proximity score [15, 16] of ARGs and
drug targets in the human protein–protein interactome.
Finally, we test the drug user’s relationship with AD using
large-scale, longitudinal patient data and further investigate drug’s mechanism-of-action using in vitro mechanistic observations in human microglia cells (Fig. 1).

Material and methods
Collection of GWAS SNPs from large‑scale studies

In this study, we assembled multiple single-nucleotide
polymorphisms (SNPs) associated with AD from 15
large-scale GWAS studies in diverse population groups,
conducted between 2007 and 2019 (Table S1). Some of
the collected SNPs may represent the same genetic signal
due to the use of overlapping samples across studies. To
avoid this bias, we filtered the collected SNPs to remove
redundant genetic signals (Supplementary Methods).
To maximize genetic signals based on the omnigenic
hypothesis [20], we adopted a loose threshold (P < 1 ×
10−5) to collect and filter AD SNPs and finally obtained
106 unique GWAS SNPs for downstream analyses.
Construction of human protein–protein interactome

To build a comprehensive human protein–protein interactome, we assembled data from 15 common resources
with multiple levels of experimental evidence (Supplementary Methods). Specifically, we focused on highquality protein–protein interactions (PPIs) with the
following five types of experimental data: (1) binary
PPIs tested by high-throughput yeast-two-hybrid (Y2H)

Fang et al. Alzheimer’s Research & Therapy

(2022) 14:7

Page 3 of 23

Fig. 1 A diagram illustrating a genotype-informed, network methodology and population-based validation for Alzheimer’s therapeutic discovery.
a A framework of network-based Bayesian algorithm (see “Material and methods”) for identifying Alzheimer’ disease (AD) risk genes. Specifically,
this algorithm integrates multi-omics data and gene networks to infer risk genes from AD GWAS loci. b Network-based drug repurposing by
incorporating ARGs and the human interactome network. c Population-based validation to test the drug user’s relationship with AD outcomes.
Comparison analyses were conducted to evaluate the predicted drug-AD association based on individual-level longitudinal patient data and the
state-of-the-art pharmacoepidemiologic methods (see “Material and methods”). d Network-based mechanistic observation. Experimental validation
of network-predicted drug’s proposed mechanism-of-action in human microglial cells. Specifically, target prioritization and drug repurposing were
conducted using network models in addition to the Bayesian algorithm. In step 1, we predicted ARGs (AD risk genes) as potential drug targets
from GWAS findings using the Bayesian algorithm. In step 2, we prioritized candidate drugs via quantifying network proximity score between drug
targets and ARGs under the human protein–protein interactome network models

systems; (2) kinase-substrate interactions by literaturederived low-throughput and high-throughput experiments; (3) literature-curated PPIs identified by affinity
purification followed by mass spectrometry (AP-MS),
Y2H, and by literature-derived low-throughput experiments, and protein three-dimensional structures; (4)
signaling network by literature-derived low-throughput
experiments; (5) protein complex data (see Supplementary Methods). The genes were mapped to their Entrez
ID based on the National Center for Biotechnology
Information (NCBI) database (www.ncbi.nlm.nih.gov),
and duplicated pairs were removed. Collectively, the
integrated human interactome included 351,444 PPIs

connecting 17,706 unique proteins. More details are
provided in our recent studies [15, 16].
Collection of functional genomics data

We collected the distal regulatory element (DRE)-promoter links inferred from two studies. The first study
was the capture Hi-C study of a lymphoblastoid cell line
(GM12878) and we obtained 1,618,000 DRE-promoter
links predicted from GM12878 [21]. The second dataset we used was from the Functional Annotation of the
Mammalian Genome 5 (FANTOM5) project [22], in
which cap analysis of gene expression (CAGE) technology was employed to infer enhancer-promoter links
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across multiple human tissues. We downloaded FANTOM5 data and obtained 66,899 enhancer-promoter
links [22].
Disease‑associated genes

Open Targets database refers to a comprehensive platform for therapeutic target identification and validation
[23]. We collected 527 AD-associated genes (Table S2)
from the Open Targets database (accessed in September, 2019).
Seed genes with experimental evidence for Alzheimer’s
disease

We further collected 144 AD seed genes having either
genetic, experimental, or functional evidence reported
in large-scale GWAS studies, AD transgenic animal
models, or human-derived samples (Table S2). These
genes are involved in pathobiology of amyloidosis,
tauopathy, or both, and genes characterizing other AD
pathological hypotheses including neuroinflammation,
vascular dementia, and other pathobiological pathways
(Supplementary Methods).
Brain‑specific gene expression

We downloaded RNA-Seq data (transcripts per million,
TPM) of 31 tissues from GTEx V8 release (accessed on
March 31, 2020, https://w ww.gtexportal.org/home/).
We defined those genes with counts per million (CPM)
≥ 0.5 in over 90% of samples as tissue-expressed genes
and the other genes as tissue-unexpressed. To quantify
the expression significance of tissue-expressed gene i
in tissue t, we calculated the average expression 〈E(i)〉
and the standard deviation δE(i) of a gene’s expression
across all tissues evaluated. The significance of gene
expression in tissue t is defined as

zE (i, t) = (E(i, t) − �E(i)�)/δE (i)

(1)

The details have been described in previous studies
[15, 16].
Gene expression from single‑cell/nucleus transcriptomics

We collected mouse single-cell/nucleus RNA sequencing (sc/snRNA-Seq) data in 5XFAD brain samples versus controls from two recent studies (GSE98969 and
GSE140511) [24, 25]. We also collected human snRNASeq datasets on AD patient brain tissues from two publications [26, 27]. The first set of human snRNA-Seq
data contains 10 frozen post-mortem human brain
tissues from both entorhinal cortex (EC) and superior frontal gyrus (SFG) regions. This dataset has been
deposited in the AD knowledge portal (https://adkno
wledgeportal.synapse.org, Synapse ID: syn21788402).

The raw data were deposited on Gene Expression
Omnibus (GEO ID: GSE147528), which contains astrocytes, excitatory neurons, inhibitory neurons, and
microglia cells [27]. We also assembled human snRNASeq data in AD cases versus controls with entorhinal
cortex samples across six major brain cell types (GEO
ID: GSE138852): microglia, astrocytes, neurons, oligodendrocytes, oligodendrocyte progenitor cells (OPCs),
and endothelial cells [26].
The original sc/snRNA-Seq datasets were downloaded
from the GEO database (www.ncbi.nlm.nih.gov/geo/),
and detailed information of these datasets is provided
in Table S3. The analyses were completed with Seurat
(v3.1.5), scran (v1.16.0), scater (v1.16.1) packages in R
with steps complied with the original literature [24–27].
Data were normalized using a scaling factor of 10,000,
and all differential gene expression analyses were conducted by function FindMarkers in the Seurat R package
with parameter test.use = “MAST.” All mouse genes were
further mapped to unique human-orthologous genes
using the Mouse Genome Informatics (MGI) database
(Eppig et al., 2017). Details of processing of sc/snRNAseq data and quality control are provided in Supplementary Methods and our recent study [18].
Gene expression from microarray

We collected human microarray data in AD cases versus healthy controls with human brain samples from two
independent datasets (GSE29378 and GSE84422) [28,
29]. We also collected mouse microarray data from AD
transgenic mouse vs. controls, including brain microglia
of 5XFAD mice from 2 independent datasets (GSE65067
and GSE74615) [30, 31], and brain hippocampus of
Tg4510 mice (GSE53480 and GSE57583) [32].
The original microarray datasets were obtained from
Gene Expression Omnibus (https://www.ncbi.nlm.nih.
gov/geo). Detailed information of these 6 GEO datasets
is provided in Table S3. All raw expression data were
log2 transformed, and all samples were quantile normalized together. Probe IDs in each dataset were mapped
to NCBI Entrez IDs, and probes mapping to multiple
genome regions or without corresponding entrez IDs
were deleted. The items were imported to R statistical
processing environment using a LIMMA/Bioconductor
package. All the mouse genes were further transferred
into unique human-orthologous genes using the MGI
database [33]. Genes with threshold fold change (FC) >
1.2 were defined as exhibiting differential expression and
prioritized as predicted AD risk genes.
Bulk RNA sequencing data

We collected 2 RNA-seq datasets from brain or brain
microglia of 5XFAD mice [34]. In addition, we obtained
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4 RNA-seq datasets from brain microglia of Tg4510 mice
across different months [M] age (2M, 4M, 6M, and 8M)
[35]. Differential expression analysis was performed
using DESeq [36], while threshold for significance of differential expression was set to FDR < 0.05 using Benjamini-Hochberg’s method. After mapping mouse genes
to human-orthologous gene [33], we obtained 6 differentially expressed gene sets.
Proteomic data in AD models

In total, 10 proteomic datasets were assembled from 3
types of AD transgenic mouse models in two recent publications [37, 38]. The first study performed global quantitative proteomic analysis in hAPP and hAPP-PS1 mouse
models at young (3 month [M]) and old ages (12 M) [37].
We obtained four sets of DEPs (hAPP_3M, hAPP_12M,
hAPP-PS1_3M, and hAPP-PS1_12M) after merging the
DEPs from different brain regions. The second study performed quantitative proteomics to uncover molecular
and functional signatures in the hippocampus of three
types of transgenic mice [38]. Two of these mouse lines,
including ADLPAPT (4M, 7M, 10M) that carry three
human transgenes (APP, PSEN1, and tau) and hAPP-PS1
(4M, 7M, 10M) mouse, were used in this study. After
mapping mouse genes to human-orthologous gene [33],
we obtained 10 sets of DEPs.
Enrichment analysis

Differentially expressed gene/protein (DEG/DEP) sets
from multiple data sources were collected for enrichment
analysis using Fisher’s exact test. This included a total
of 6 bulk RNA-seq datasets and 10 proteomic datasets
from 4 types of AD transgenic mouse models, including
5XFAD, Tg4510, ADLPAPT, and hAPP (see Supplementary Methods).
AD risk gene prediction

We utilized a Bayesian model selection method, adapted
from our recent work [17], to predict ARGs. Specifically,
we collected at most 20 genes in the 2-Mb region centered at a GWAS index SNP as the candidates for that
particular locus. Assigning L as the number of GWAS
loci, and we then denoted a vector of genes with length
L, each being from one of the L GWAS loci, as (X1, …,
XL), and termed it as candidate risk gene set (CRGS).
Assigning N to represent the biological network, we then
calculated P (X1,…, XL|N) with the goal to select a CRGS
with maximum posterior probability. Computationally,
it is not feasible to enumerate all possible gene combinations, and we therefore adopted a Gibbs sampling algorithm to transition the problem into a single-dimensional
sampling procedure. For example, when sampling the
risk gene from candidates at the Lth locus, we assumed

Page 5 of 23

that the risk genes at all other L-1 loci had been selected,
and the sampling probability for a gene at the Lth locus
was computed as conditional on the L-1 risk genes, based
on its closeness to other L-1 risk genes in the network.
For each candidate gene XL at the Lth locus, we assigned
M1 to represent the event that XL is the risk gene at locus
L, M0 represent the event that XL is not the risk gene at
locus L, and X-L to represent all the selected risk genes in
the other L-1 loci. The Bayesian model selection can be
depicted as

P(M1 |X−L , N )
P(M1 ) P(X−L |M1 , N )
=
P(M0 |X−L , N )
P(M0 ) P(X−L |M0 , N )

(2)

P(X−L |M1 , N )
where P(X
is a Bayesian Factor (BF) measuring
−L |M0 , N )
P(M1 )
the closeness between X-L and XL in network N and P(M
0)
is prior odds. The prior odds reflect the prior knowledge
whether XL is a risk gene or not and we assumed P(M1) =
P(M0) in this study.
P(X−L |M1 , N )
In regard to P(X
, we adopted the random walk
−L |M0 , N )
with restart (RWR) algorithm to calculate the BF. Starting
from any node ni in a predefined network N, the walker
faces two options at each step: either moving to a direct
neighbor with a probability 1 − r or jumping back to ni
with a probability r. The fixed parameter r is called the
restart probability in RWR, and r was set as 0.3 in this
study [17]. Let W be the adjacency matrix that decides
which neighbor to be moved to, and qt be the reaching
probability of all nodes at step t. The RWR algorithm is
formalized as

qt+1 = (1 − r)Wqt + rsni

(3)

sni is a vector with the ith element as 1 and 0 for
others, which means th starting node is ni. Following the equation, qt can be updated step by step until
|qt + 1 − qt|2 < Trwr, where Trwr is a predefined threshold.
We set Trwr as 1 × 10−6 [17]. The adjacency matrix W
represents the distance between any two nodes in the
network, and we adopted the same network and strategy in our previous work to calculate W. We calculated
P(X−L| M1,   N) based on W. We mapped XL to the rows
of W and X−L to the columns of W, and obtained a vector
with the same length as X−L. The sum of the vector was
calculated as P(X−L| M1,   N). In this study, we assumed
P(X−L| M0,   N) to be the same for all different candidate
genes. Through the Bayesian model selection equation,
P(M1 |X−L , N )
P(M1 ) P(X−L |M1 , N )
=
P(M0 |X−L , N )
P(M0 ) P(X−L |M0 , N )

(4)

we obtained a value for each candidate genes at locus
L. We used these values as sampling for Gibbs sampling
to choose a risk gene for locus L. We then repeated the
sampling across the remaining loci and iterated the
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sampling process until convergence. Specially, in each
round of Gibbs sampling, we calculated the sampling frequency for each candidate gene. The frequency was compared with that of the previous round, and if the sum of
squares of frequency differences across all selected genes
was smaller than a predefined threshold (1 × 10−4 used
in this study), then the sampling procedure was halted.
Based on the sampling, we are able to assess the confidence of candidates being risk genes.
Construction of drug‑target network

We integrated six commonly used resources to collect
high-quality physical drug-target interactions for FDAapproved drugs. We obtained biophysical drug-target
interactions using reported binding affinity data: inhibition constant/potency (Ki), dissociation constant (Kd),
median effective concentration (EC50), or median inhibitory concentration (IC50) ≤ 10 μM. First, we extracted
the bioactivity data from the DrugBank database (v4.3)
[39], the Therapeutic Target Database (TTD, v4.3.02)
[40], and the PharmGKB database [41]. To improve data
quality, we pooled only those items that satisfied the following four criteria: (i) binding affinities, including Ki,
Kd, IC50, or EC50, ≤ 10 μM; (ii) the target protein has a
unique UniProt accession number; (iii) proteins marked
as “reviewed” in the UniProt database; and (iv) proteins are from Homo sapiens. Totally, we constructed a
drug-target network including 15,367 physical drugtarget interactions (edges), which connected 1608 FDAapproved drug nodes and 2251 unique human target
nodes (Table S4).
Description of network proximity

Given the set of disease proteins (A), the set of drug targets (B), then the closest distance dAB measured by the
average shortest path length of all the nodes to the other
module in the human protein–protein interactome can
be defined as:



dAB =

mean d and standard deviation (σd) of the reference distribution were used to caluculate a z-score (zd) by converting an observed (non-Euclidean) distance d to a
normalized distance.
Pharmacoepidemiologic validation
Patient cohort preparation

The pharmacoepidemiology study utilized the MarketScan Medicare Supplementary database from 2012
to 2017. The dataset included individual-level diagnosis
codes, procedure codes, and pharmacy claims for 7.23
million U.S. older adults (i.e., age ≥ 65 to be eligible for
Medicare benefits) per year, which represents approximately 14% of the 46 million retirees with Medicare benefits. Pharmacy prescriptions of pioglitazone, febuxostat,
atenolol, nadolol, sotalol, and glipizide were identified
by using RxNorm and National Drug Code (NDC). For
a subject exposed to the aforementioned drugs, a drug
episode is defined as the time between drug initiation
and drug discontinuation. Specifically, drug initiation
is defined as the first day of drug supply (i.e., first prescription date). Drug discontinuation is defined as the
last day of drug supply (i.e., last prescription date + days
of supply) accompanied by no drug supply for the next
60 days. Gaps of less than 60-day of drug supply were
allowed within a drug episode. For example, the pioglitazone cohort included the first pioglitazone episode
for each subject, as well as the glipizide cohort. Further,
we excluded observations that started within 180 days of
insurance enrollment. For the final cohorts, demographic
variables including age, gender and geographical location were collected. Additionally, diagnoses of hypertension (HTN), type 2 diabetics (T2D), and coronary artery
disease (CAD), defined by The International Statistical
Classification of Diseases (ICD) 9/10 codes (Supplementary Methods, Table S5), before drug initiation, were
collected. These variables were specifically selected to
address potential confounding biases. Lastly, a control
cohort was selected from patients not exposed to that





1
minb∈B d(a, b) +
mina∈A d(a, b)
||A|| + �B�
a∈A

(5)

b∈B

where d(a, b) denotes to the shortest path length
between protein a and drug target b.
To calculate the significance of the network distance
between a given drug and disease module, we constructed a reference distance distribution corresponding
to the expected distance between two randomly selected
groups of proteins of the same size and degree distribution as the original disease proteins and drug targets in
the network. This procedure was run 1000 times. The

drug (i.e., pioglitazone). Specifically, non-exposures were
matched to the exposures (ratio 1:4) by initiation time of
the drug, enrollment history, age, and gender. The geographical location, diagnoses of HTN, T2D, and CAD
were collected for the control cohort as well.
Outcome measurement

The outcome was time from drug initiation to diagnosis of AD, which was defined by using the ICD codes
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(Supplementary Methods). For the control cohort, the
corresponding drug (i.e., pioglitazone) episode’s starting date was used as the starting time. For pioglitazone
and glipizide cohorts, observations without diagnose
of AD were censored at the end of drug episodes.
Observations without diagnosis of AD were censored
at the corresponding pioglitazone episode’s end date
(Fig. S1).
Propensity score estimation

We define Location = region of residence (i.e., North
East, North Central, South, and West), T2D = type 2 diabetes, HT = hypertension, and CAD = coronary artery
disease.
The propensity score of taking repurposing drug vs. a
comparator drug was estimated by the following logistic
regression model:
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Experimental validation
Reagents

Pioglitazone was acquired from Topscience. Lipopolysaccharides (LPS) (Cat# L2880) and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) were
obtained from Sigma-Aldrich. Antibodies against Phospho-GSK3B-Y216 (Cat# AP0261), GSK3B (Cat# A2081),
and CDK5 (Cat# A5730) were purchased from ABclonal
Technology. CDK5-Phospho-Tyr15 (Cat# YP0380) was
obtained from Immunoway (Plano, Texas, USA). All
other reagents were purchased from Sigma-Aldrich
unless otherwise specified.
Cell viability

Human microglia HMC3 cells were purchased from
American Type Culture Collection (ATCC, Manassas,
VA). Cell viability was detected by MTT method. In total,

logit[Propensity Score] ∼ Intercept + Age + Gender + Location + T 2D + HT + CAD.
Stratified Cox models were used to compare the AD
risks. For repurposing drug vs. comparator drug or
control, the analyses were stratified (n strata = 10) by
the estimated propensity score. The propensity score
adjusted Cox model is

(6)

5000 cells/well were plated in 96-well plates for 12 h,
and then treated with pioglitazone for 48 h. After treatment, MTT solution was added to the cells to a final concentration of 1 mg/mL, and the mixture was allowed to
incubate at 37 °C for 4 h. The supernatant was removed,

log[Hazard] ∼ Strata[log(Baseline Hazard)|Propensity Score]+1[Repurposing drug yes].

(7)

For repurposing drug vs. control, the analyses were
stratified based on the subgroups defined by gender, T2D
diagnose, HT diagnoses, and CAD diagnoses.

and precipitates were dissolved in DMSO. Absorbance
was measured at 570 nm using a Synergy H1 microplate
reader (BioTek Instruments, Winooski, VT, USA).

Statistical analysis

Western blot analysis

Survival curves for time to AD were estimated using a
Kaplan-Meier estimator. Additionally, propensity score
stratified survival analysis was conducted to investigate the risk of AD between pioglitazone users and
pioglitazone non-users, febuxostat users and febuxostat non-users, atenolol users and atenolol non-users,
nadolol users and nadolol non-users, and sotalol users
and sotalol non-users. In addition, we conducted new
comparison studies to calculate the risk of AD between
pioglitazone users and glipizide users. For each comparison, the propensity score of taking each drug was
estimated by using a logistic regression model in which
covariates included age, gender, geographical location,
T2D diagnosis, HTN diagnosis, and CAD diagnoses.
Furthermore, propensity score stratified Cox-proportional hazards models were used to conduct statistical
inference for the hazard ratios (HR) of developing AD
between cohorts.

HMC3 cells were pre-treated with pioglitazone (3 μM or
10 μM) and DMSO (control vehicle), and followed with
1 μg/mL LPS for 30 min. Cells were harvested, washed
with cold PBS, and then lysed with RIPA Lysis Buffer with
1% Protease Inhibitor (Cat# P8340, Sigma-Aldrich). Total
protein concentrations were measured using a standard
BCA protein assay kit (Bio-Rad, CA, USA), according
to the manufacturer’s manual. Samples were electrophoresed by sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE), then blotted onto a polyvinylidene difluoride (PVDF; EMD Millipore, Darmstadt,
Germany) membrane. After transferring, membranes
were probed with specific primary antibodies (1:1000)
at 4 °C overnight. Specific protein bands were detected
using a chemiluminescence reagent after hybridization
with a horseradish peroxidase (HRP)-conjugated secondary antibody (1:3000).

Fang et al. Alzheimer’s Research & Therapy

(2022) 14:7

Results
Pipeline of the network‑based artificial intelligence
methodology

We utilized a Bayesian model selection method to predict
ARGs [17], based on the assumption that likely causal
risk genes are more densely connected with each other
in a biological network (Fig. 1a). By applying this Bayesian model to the 106 AD GWAS loci after being filtered
the redundant genetic signals from original 366 SNPs
(“Material and methods” and Table S1), we predicted 103
ARGs after merging the overlapping genes across several
different loci (Table S6). Meanwhile, we also predicted a
set of local background genes (LBGs) as a negative control for the following analyses [17]. We validated our
103 ARGs using multi-omics data, including functional
genomic characteristics and transcriptomics, as well as
proteomic profiles generated from diverse AD transgenic
mice models and AD patient brain samples.
Multi‑omics validation of network‑predicted risk genes
in AD

Recent studies showed that disease-associated proteins
tend to cluster in the same neighborhood of the human
protein–protein interactome, forming a disease module,
a connected subgraph that contains molecular determinants of a disease [15, 16]. Disease modules are commonly used to represent the molecular determinants of
disease pathobiology/physiology in a variety of human
diseases, including AD [8]. We found that 103 ARGs
formed significantly connected subgraphs (termed disease module) rather than being scattered randomly in
the human protein–protein interactome (Supplementary Methods), consistent with previous disease module
analyses that we demonstrated in other multiple complex
diseases [15, 16]. Specifically, 68.0% of ARGs (70/103, P
= 0.015, permutation test) form the largest connected
subnetwork (disease module), in comparison to the same
number of randomly selected genes with similar connectivity (degree) as the original seed genes in the human
interactome (Fig. S2). This disease module (Fig. 2a)
includes 128 PPIs (edges or links) connecting 70 unique
genes (nodes). Network analysis revealed 14 genes with
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connectivity higher than 5, the top five of which were
ESR1, PSMC5, MAPK1, PAK1, and NFKB1. These same
five genes have previously been implicated in AD [42–
45]. For example, ESR1 interacts with tau protein in vivo,
and prevents glutamate excitotoxic injury by Aβ via
estrogen signaling [42]. Gene expression analysis shows
that PSMC5 was significantly overexpressed in patients
carrying apolipoprotein E-ε4 (APOE4) mutations in comparison to APOE wild-type group [43]. In summary, 103
predicted ARGs comprise a strong disease module in the
human interactome.
Because a majority of GWAS SNPs lie in noncoding
region and exert their function by gene regulation [46],
we explored the gene regulatory elements of ARGs by
testing the hypothesis that the network-predicted risk
genes capture more distal regulatory element (DRE)-promoter connections compared to 571 LBGs. We collected
DRE-promoter connection data generated by two technologies: CAGE from FANTOM5 project and capture
Hi-C (see “Material and methods”) [22, 47]. Through this,
we found that the ARGs are indeed connected to more
DREs in both capture Hi-C data (adj-P = 7.76 × 10−3,
Fig. 2b) and FANTOM5 data (adj-P = 0.028, Fig. 2c).
We next investigated differential expression of ARGs
under different pathobiology contexts of AD. We measured fold changes of gene expression levels of ARGs
across 4 sc/snRNA-seq datasets (Table S3) compared to
571 LBGs. We found that ARGs were more likely to be
differentially expressed in all sc/snRNA datasets (Fig. 2d–
k). ARGs were more likely to be differentially expressed
in (i) 5XFAD mouse brain microglial cells (Fig. 2d,e);
(ii) human astrocyte cells of entorhinal cortex (Fig. 2f )
and the superior frontal gyrus (Fig. 2g) from individuals spanning the neuropathological progression of AD;
and (iii) a human single-cell atlas of entorhinal cortex
from AD patients across four brain cell types: microglia (Fig. 2h), neuron (Fig. 2i), oligodendrocyte (Fig. 2j),
and oligodendrocyte progenitor cell (OPC) (Fig. 2k). We
further performed differentially expressed gene enrichment analysis for network-predicted ARGs in AD using
bulk tissue expression data (Supplementary Methods).
We collected bulk RNA-seq data from whole brain tissue

(See figure on next page.)
Fig. 2 Network-based validation of predicted risk genes for Alzheimer’s disease (AD). a A subnetwork highlighting disease module formed by
predicted AD risk genes (ARGs) in the human protein–protein interactome. This disease module includes 128 protein–protein interactions (PPIs)
(edges or links) connecting 70 ARGs (nodes). Larger node size highlighting the high expression level in brain compared to other tissues. b–k
Discovery of genomic features of 103 predicted ARGs implicated in AD. ARGs capture strong distal gene regulatory elements in Hi-C (b) and
FANTOM5 data (c) compared to a set of local background genes (LBGs). d–k AGRs are more likely to be differentially expressed across 4 single-cell/
nucleus RNA sequencing datasets (Table S3): d, e brain microglia cell of 5XFAD mouse model (GSE98969 [d] and GSE140511 [e]); f,g a human
single-cell atlas (GSE147528) of entorhinal cortex (f) and the superior frontal gyrus (g) from individuals spanning the neuropathological progression
of AD patient brain astrocyte cells; and a single-cell atlas (GSE138852) of entorhinal cortex from AD patients across four brain cell types: microglia
[h], neuron [i], oligodendrocyte [j], oligodendrocyte progenitor cell (OPC) [k]. P value was computed by one-tail T-test. Adjusted P value (adj-P) was
calculated based on the Benjamini−Hochberg approach. LCC: largest connected component; EC: entorhinal cortex; SFG: superior frontal gyrus
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or brain microglial cells from two common AD transgenic mouse models (5XFAD and Tg4510) and observed
that ARGs were significantly differentially expressed in
5XFAD brain (P = 0.003), 5XFAD microglial cells (P =
0.002), and brain microglia of Tg4510 (Table S7). This
suggests that our identified ARGs are potentially involved
in diverse pathobiological pathways of AD.
We further inspected differentially expressed proteins encoded by 103 network-predicted ARGs across
10 published proteomics datasets (see Supplementary
Methods) in AD. Herein, we evaluated 3 types of AD
transgenic mouse models: (a) hAPP model containing APP transgene, (b) 5XFAD model harboring human
transgenes for both APP and PSEN1 mutations, and (c)
ADLPAPT model carrying three human transgenes
(APP, PSEN1, and MAPT). We found that products of
ARGs were significantly differentially expressed in all 3
AD transgenic mouse models (P < 0.05, Fisher test, Table
S7).
Collectively, we have thus shown that network-predicted ARGs are significantly involved in disease-related
functional genomic, transcriptomic, and proteomic profiles, supporting their functional role as likely causal
genes for AD.
Incorporation of AD multi‑omics data to prioritize ARGs

We next turned to prioritize high-confidence ARGs by
integrating multi-omics profiles. In total, we incorporated 8 criteria that can be categorized into 5 types of biological evidence: (1) brain-expression specificity (z-score)
derived from GTEx database, (2) availability of supportive experimental evidence from the literatures and manually curated data from Open Targets database [23], (3)
experimentally validated AD genes, (4) differential gene
expression from microarrays, and (5) available drug targets. Figure 3 shows a global view of 103 ARGs that we
validated by these multiple forms of biological evidence
in AD. Among 103 ARGs, 89 genes (86.4% [89/103]) satisfy at least one criterion. To validate the remaining 14
ARGs without any omics evidence, we further collected
significantly expressed proteins or genes from the most
recent human AD brain proteomic or transcriptomic
studies [26, 48–51]. We found that 7 were significantly
expressed in five recent human AD brain proteomics or
sc/snRNA-seq datasets (Table S8). In addition, among
103 ARGs, 13 ARGs have at least 5 types of AD-related
evidence, including 8 well-known AD genes: APOE,
PTK2B, NOS1, MEF2C, SORL1, EPHA5, ADAM10, and
CD33. For the rest of the ARGs, all but BRSK1 had corresponding published literature-derived evidence. For
example, PAK1 is a predicted risk gene with 6 criteria
of biological evidence: high brain expression specificity (z-score = 1.01), supportive experimental evidence
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from the literature, druggable target data, and differential expression in human brain of AD patients, microglial
cells of 5XFAD mouse model, and brain hippocampus of
a tau mouse model (Fig. 3 and Table S8). P21-activated
kinase 1, encoded by the PAK1 gene, has been implicated
in AD [52], and recent studies have revealed that inactivation of PAK1 obliterated social recognition without
changing amyloid beta (Aβ)/tau pathology, and also exacerbated synaptic impairment and behavioral deficits in
mouse models of AD [53, 54].
Among 103 ARGs, we selected 37 likely causal genes
(Table S8) using subject matter expertise based on a combination of factors: (i) high brain-expression specificity, (ii) differential expression in multiple AD transgenic
mouse models; (iii) strength of the network-based prediction, and (iv) availability of supportive experimental
evidence. To advance disease understanding of networkpredicted high-confidence risk genes, we performed
biological pathway enrichment analysis using ClueGO
plugin in Cytoscape (Table S9) [55]. We found 4 statistically significant biological pathways in AD and further
discussed as below: (a) regulation of neurotransmitter
transport, (b) Aβ-related biologic process, (c) long-term
synaptic potentiation, and (d) oxidative stress (Table 1
and Table S10).
Neurotransmitter transport

Specifically, MEF2C and RIMS1, encoding myocytespecific enhancer factor 2C and regulating synaptic
membrane exocytosis protein 1, play key roles in neurotransmitter secretion and synaptic plasticity. MEF2C
(rs254776) has been reported in several AD GWAS studies [56, 57], and we found significantly lower expression
of MEF2C in AD brain (adj-P = 0.010, one side Wilcoxon test, Fig. S3a). RIMS1 is a newly predicted ARG,
and a recent proteome study from human hippocampus
revealed its overexpression in AD [58]. RIMS1 is significantly overexpressed in 5XFAD mouse microglia (adj-P
= 0.036, one side Wilcoxon test) compared to controls
(Fig. S3b).
Beta‑amyloid‑related biologic process

Five genes (APOE, ADAM10, CHRNA7, SORL1, and
LRP2) are associated with beta-amyloid biologic process.
Among them, APOE, ADAM10, and SORL1 are wellknown AD risk genes, validated by large-scale genetic
studies and preclinical studies [6, 59, 60]. For example,
APP cleavage by ADAM10 will produce an APP-derived
fragment that is neuroprotective, sAPPα [61]. CHRNA7
(neuronal acetylcholine receptor subunit alpha-7) and
LRP2 (low-density lipoprotein receptor-related protein
2) are two newly identified risk genes. There is a significantly lower expression level of CHRNA7 in the Tg4510
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Fig. 3 Multi-omics validation of network-predicted risk genes for Alzheimer’s disease (AD). Circle plot shows all 103 predicted AD risk genes
validated by multiple-scale biological evidence. In total, 8 types of biological evidence were evaluated: (1) Brain-expression specificity derived
from GTEx database (z-score > 0 as a high brain-specific expressed gene); (2) literature evidence validation for the gene associated with AD;
(3) drug target information; (4) literature-derived experimental data from Open targets database; (5) high-quality experimentally validated
AD-associated genes; (5–8) transcriptomics-based evidence (Table S3): (6) differential expression (DE) in AD patient brains; (7) differential expression
in brain microglia cells of 5XFAD mouse model; (8) differential expression in brain hippocampus of Tg4510 mouse model. Gray bar denotes the
number of biological evidence. A total of 13 selected risk genes involved in four AD key pathways are highlighted by red: including regulation of
neurotransmitter transport, Aβ metabolic process, long-term synaptic potentiation, and oxidative stress

mouse (adj-P = 3.64 × 10−3) compared to controls (Fig.
S3e). CHRNA7 binds to Aβ with a high affinity [62].
Finally, a previous study showed that the rs3755166 polymorphism within LRP2 is associated with susceptibility
to AD in the Chinese population [63].

Long‑term synaptic potentiation

Mitogen-activated protein kinase (MAPK1) and PTK2B
are two identified risk genes related to long-term synaptic potentiation. Mitogen-activated protein kinase 1,
encoded by MAPK1 gene, is highly expressed in brain
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Table 1 Network-predicted risk genes involved in four pathobiological pathways of Alzheimer’s disease (AD)
Gene

Protein

Description

MEF2Ca

Myocyte-specific enhancer factor 2C

MEF2C mRNA expression levels were correlated with
AD pathology

RIMS1

Regulating synaptic membrane exocytosis protein 1

An altered protein expression in RIMS1 during AD
pathology

Neurotransmitter transport

Beta-amyloid-related biologic process
APOEa

Apolipoprotein E

Affect Aβ production, aggregation, and clearance

CHRNA7

Neuronal acetylcholine receptor subunit alpha-7

Bind to Aβ with very high affinity, providing thera‑
peutic insight into AD

SORL1a

Sortilin-related receptor

Reduce Aβ generation by trafficking APP away from
amyloidogenic cleavage sites

ADAM10a

Disintegrin and metalloproteinase domain-contain‑
ing protein 10

Constitutive α-secretase in the process of amyloid-β
protein precursor (AβPP) cleavage

LRP2

Low-density lipoprotein receptor-related protein 2

rs3755166 polymorphism within LRP2 gene is
associated with susceptibility to AD in the Chinese
population

MAPK1

Mitogen-activated protein kinase 1

Beta-amyloid activates the MAPK cascade via hip‑
pocampal CHRNA7

PTK2Ba

Protein-tyrosine kinase 2-beta

An in vivo modulator and early marker of Tau pathol‑
ogy

FOXO3

Forkhead box protein O3

Activate BCL2L11 and FASLG to promote neuronal
death and aberrant Aβ processing

NOS1

Nitric oxide synthase

Loss of endothelial NOS promotes p25 production
and Tau phosphorylation

NFKB1

Nuclear factor NF-kappa-B p105 subunit

Involve in neuroinflammation, synaptic plasticity,
learning, and memory implicated in AD

ESR1

Estrogen receptor

Interact with tau protein in vivo, and prevent glu‑
tamate excitotoxic injury by Aβ through estrogen
signaling mechanisms

Long-term synaptic potentiation

Oxidative stress

a

Genes have experimental or functional evidence reported in AD transgenic animal models or human-derived samples (see Table S2 and Supplementary Method).
The detailed literature data are provided in Table S2

tissue (z-score = 1.42). The MAPK1 cascade can be activated by Aβ via alpha7 nicotinic acetylcholine receptors
[64]. PTK2B, a well-known AD gene with high expression in brain (z-score = 0.90), was identified as an early
marker and in vivo modulator of tau pathology [65], by
mediating Aβ-induced synaptic dysfunction and loss
[66]. There is significantly lower expression of PTK2B in
AD patient brain transcriptome (adj-P = 2.05 × 10−5)
compared to controls (Fig. S3g).
Oxidative stress

Oxidative stress is a prominent hypothesis in the pathogenesis of AD [67]. Here we found four network-predicted ARGs (FOXO3, NOS1, NFKB1, and ESR1) that
were associated with regulation of oxidative stress.
FOXO3 encoding Forkhead box protein O3 transcription
factor is a direct substrate of CDK5. FOXO3 activates
several genes (e.g. BCL2L11 and FASLG) to promote

neuronal death and aberrant Aβ processing [68]. Significantly lower expression of FOXO3 was found in 5XFAD
mouse microglia (adj-P = 6.90 × 10−3) compared to controls (Fig. S3h). NFKB1, encoding transcription factor
nuclear factor kappa B (NF-κB), is implicated in oxidative
stress, synaptic plasticity, and learning and memory [69].
Taken together, these findings suggest that our network-predicted ARGs are involved in diverse pathobiological pathways of AD. However, experimental
validations are warranted for several newly predicted
ARGs.
Network‑predicted ARGs are more likely to be drug targets

To date, most disease genes generated from GWAS findings are undruggable [70]. For example, a recent study
revealed that none of approved and investigational AD
drugs target products (proteins) of GWAS-derived genes
in AD [71]. We examined whether network-predicted
ARGs were more druggable compared to randomly
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selected proteins from human protein-coding gene background. Based on drug-target networks from 6 commonly used resources (see “Material and methods”), we
obtained 2866 potential druggable proteins for FDAapproved or clinically investigational drugs. Surprisingly,
we found that 41 out of 103 predicted ARGs (39.8 %)
are known druggable proteins, which is four-fold higher
than druggable proteins (P = 9.25 × 10−11, Fisher test)
in the genome-wide human protein-coding genome
background. High druggability of network-predicted
ARGs offers more candidate targets for therapeutic discovery (such as drug repurposing) in AD. For example,
ADRA2A, one of the predicted ARGs, encodes adrenoceptor alpha 2A receptor. ADRA2A is a potential target of
clozapine [72], an atypical antipsychotic drug. Long-term
clozapine treatment reduces Aβ deposition and improves
cognitive impairment in an AD transgenic mice model
[73]. NR1I3, encoding the nuclear receptor constitutive androstane receptor (CAR), is a potential drug target activated by the lipid-lowering drug simvastatin [74].
Simvastatin was reported to significantly reduce levels of
Aβ in vitro and in vivo [75, 76]. In summary, networkpredicted ARGs showed higher druggability compared
to traditional GWAS-based analysis approaches. We next
examined opportunities for drug repurposing by integrating findings from ARGs with the human protein–
protein interactome network.
ARGs offer candidate targets for Alzheimer’s drug
repurposing

We have identified that network-predicted ARGs are
related to the known pathobiology of AD and offer potential druggable targets, prompting us to examine opportunities for AD therapeutic discovery. We hypothesized that
for a drug with multiple targets to be beneficial for treating a disease, its target proteins should be within or in the
immediate vicinity of the corresponding disease module
(Fig. 2a) in the human interactome network. To examine
the potential application of ARGs on AD drug repurposing, we applied a network proximity approach [15] to
quantify the interplay between AD modules from ARGs
and drug targets in the human interactome network. We
used the cutoff of z-score (z < − 1.5) to select networkpredicted repurposable drugs in AD. After exclusion of
nutraceutical drugs, metal drugs, and radioactive diagnostic agents, 130 drug candidates were obtained. We
then systematically retrieved the published anti-AD clinical, in vitro/in vivo reported data for the 130 predicted
drugs. In total, 25 had corresponding preclinical or clinical evidence for potential application to AD (Table S11).
Figure 4 shows the molecular mechanisms of the 25 predicted drug candidates with published experimental or
clinical evidence for AD. These drugs are classified into 6
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categories according to Anatomical Therapeutic Chemical
classification (ATC) codes: musculoskeletal systems (n =
6), genitourinary system and hormones (n = 5), cardiovascular (n = 3), alimentary tract and metabolism (n = 3),
respiratory system (n = 2), and others (n = 6).
Among them, we found 4 predicted drugs having
known AD clinical evidence [77, 78], including febuxostat [79], pioglitazone (NCT02913664), carvedilol
(NCT01354444), and fluticasone [77]. Febuxostat, a xanthine oxidase (XO) inhibitor approved for hyperuricemia,
exerts a significant network proximity (z = − 1.60) with
the ARGs. Pioglitazone, an FDA-approved drug for T2D,
has a significant network proximity (z = − 1.64) with the
ARGs. Figure 4 shows that pioglitazone targets six proteins by connecting with 12 neighborhoods of ARGs.
Network‑predicted pioglitazone usage reduces risk of AD
in patient data

To test both the febuxostat and pioglitazone users’ relationships with AD outcomes using population-based
validation, we conducted 2 rigorous retrospective casecontrol studies to compare AD risk by analyzing 7.23
million U.S. commercially insured individuals (“Material and methods”). These included the following: (i)
pioglitazone (n = 101,650, z = − 1.64 [network proximity score between ARGs and drug targets in the human
interactome network]) vs. a matched control population
(control, n = 402,488), and (ii) febuxostat (n = 24,218, z
= − 1.60) vs. control (n = 95,192). In order to identify
more drug candidates with potential of reducing risk
of AD, we conducted another 3 rigorous retrospective
case-control studies for 3 antihypertensive agents with
moderate z-score (z > − 1.0). These included the following: (iii) atenolol (n = 366,277, z = − 1.16) vs. control (n
= 1,449,815); (iv) nadolol (n = 19,253, z = − 1.26) vs.
control (n = 76,136); and (v) sotalol (n = 43,819, z = −
1.512) vs. a control (n = 172,375). Table 2 summarizes
the patient data for pharmacoepidemiologic analyses. For
each comparison, we estimated the unstratified KaplanMeier curves, conducted by both propensity score stratified (n strata = 10) log-rank test and Cox model. After 6
years of follow-up, pioglitazone (P = 0.005, hazard ratio
(HR) = 0.916, 95% confidence interval [CI] 0.861–0.974),
febuxostat (HR = 0.815, 95% CI 0.710–0.936, P = 0.004),
and atenolol (HR = 0.949, 95% CI 0.923–0.976, P = 2.8 ×
10−4) are associated with a reduced risk of AD compared
with matched control populations (Figs. 5 and 6).
Several clinical trials have been conducted with pioglitazone to treat AD. A phase II study (NCT00982202)
showed no statistically significant difference between
controls and patients with mild to moderate AD [80].
However, another study showed that pioglitazone was
associated with cognitive and functional improvement, as
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Fig. 4 Risk gene-informed drug repurposing for Alzheimer’s disease (AD). a A Sankey diagram illustrates a global view of 25 repurposable drug
candidates with published evidence for AD. These drugs are linked to their physical binding targets or neighborhood proteins derived from
network-predicted AD risk genes. b Network proximity analysis measures the network distance between disease module and drug targets in the
human interactome. A subnetwork indicates the molecular mechanism of pioglitazone implicated in AD, which targets six physical binding proteins
of which neighborhoods are 12 predicted AD risk genes. c Drugs are grouped by their first-level Anatomical Therapeutic Chemical Classification
(ATC) codes. The drugs with known anti-AD clinical status, in vitro and in vivo mouse model published data are given. Pioglitazone and febuxostat
with anti-AD clinical evidence are highlighted

well stabilization of AD in 42 diabetic patients [81]. Many
of these studies were conducted in populations without
biological confirmation of AD by biomarkers, and in
some cases (e.g., the TOMMOW study; NCT01931566),
the dose of pioglitazone was substantially lower than that
used in clinical practice for the treatment of diabetes.
The available clinical trial data do not exclude a beneficial
effect of pioglitazone on AD. Except for the TOMMOW
study that was conducted in cognitively normal at-risk
individuals, other trials examined symptomatic patients
that addressed a question different from the risk-reduction interrogation we prosecuted. For these reasons, we
chose pioglitazone to conduct new comparison analysis
to reduce unobserved bias.
In pharmacoepidemiologic studies, a comparator drug
sharing similar indications with the investigational drug
is usually selected as a “control drug” [82]. This approach
is able to reduce unobserved bias, as the comparator drug

and the investigational drug are likely to target the same
population. Since both of pioglitazone and glipizide are
treated for T2D, we therefore selected glipizide as a comparator drug. We next conducted new comparison analyses between pioglitazone and glipizide (an anti-T2D drug,
n = 191,656) to evaluate the predicted association based
on individual-level longitudinal patient data and a novel
user active comparator design (“Material and methods”).
New comparison analyses confirm that pioglitazone is
associated with a reduced risk of AD in comparison to
glipizide (HR = 0.921, 95% CI 0.862–0.984, P = 0.0159,
Fig. 5). Thus, two independent comparison analyses support our network-based prediction for pioglitazone.
In vitro observation of pioglitazone’s mechanism‑of‑action
in AD

Figures 5 and 6 reveal that pioglitazone significantly
reduces risk of AD in longitudinal patient-based data.

Sample size

# of AD

Female (%)

Mean Age (SD)

191,656

402,488

Glipizide

Control

5230

3048

1244
38.3

44.8

38.5

95,192

Control

1168

243

1,449,815

Control

76,136

Control

172,375

Control

46

46

60

60

58

58

37.0

37.2

76.1 (7.5)

76.4 (7.7)

75.2 (7.5)

73.7 (7.8)

75.2 (7.5)

74.5 (8.0)

75.7 (7.4)

75.1 (7.9)

74.5 (7.2)

74.2 (7.1)

72.8 (6.9)

25

19

24

29

24

24

24.7

23.5

24.2

21.5

17.7

Northeast

31

29

30

25

30

26

31.6

23.8

31.4

27.6

28.4

North Central

Geographical location (%)

30

38

30

35

30

29

30.3

37.7

30.5

31.4

35.6

South

13

14

14

10

14

21

12.7

14.4

13

18.7

17.3

West

0.8

0.5

1.1

0.8

1.1

0.7

0.8

0.6

1

0.8

0.9

NA

30

35

12

11

12

11

26.7

28.0

13.5

17.1

11.3

CAD (%)

22

22

19

18

16

14

34.1

35.3

44.6

59.4

51.2

T2D (%)

50

50

40

34

38

34

58.1

58.6

41.1

43.0

34.2

HTN (%)

We estimated the unstratified Kaplan-Meier curves, conducted propensity score stratified (n strata = 10) log-rank test and Cox model. CAD coronary artery disease, T2D type 2 diabetes, HTN hypertension, SD standard
deviation

43,819

Sotalol

Sotalol (repurposing drug), and matched control

19,253

Nadolol

Nadolol (repurposing drug), and matched control

366,277

Atenolol

Atenolol (repurposing drug), and matched control

24,218

Febuxostat

Febuxostat (repurposing drug), and matched control

101,650

Pioglitazone

Pioglitazone (repurposing drug), glipizide (comparative drug) and matched control

Group

Table 2 Statistics of patient data used for pharmacoepidemiologic analysis
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Fig. 5 Longitudinal analyses reveal that pioglitazone reduces incidence of Alzheimer’s disease in patient data. Six comparison analyses were
conducted including (i) pioglitazone (n = 101,650) vs. matched control population (n = 402,184); (ii) pioglitazone vs. glipizide (a diabetes drug,
n = 191,656); (iii) febuxostat (n = 24,218) vs. control (n = 95,192); (iv) atenolol (n = 366,277) vs. control (n = 1,449,815); (v) nadolol (n = 19,253)
vs. control (n = 76,136); and (vi) sotalol (n = 43,819) vs. control (n = 172,375). First, for each comparison, we estimated the propensity score by
using the variables described in Table 2. Then, we estimated the unstratified Kaplan-Meier curves, conducted propensity score stratified (n strata
= 10) log-rank test and Cox model. Using propensity score stratified survival analyses, non-exposures were matched to the exposures (ratio 4:1) by
adjusting the initiation time of drug, enrollment history, age and gender, and disease comorbidities (hypertension, type 2 diabetes and coronary
artery disease)

To further investigate its mechanism-of-action in AD,
we performed a network analysis through integration of
drug targets and ARGs into the brain-specific PPI network (see “Material and methods”). Network analysis
shows that pioglitazone potentially targets two tauopathy-related proteins (GSK3β and CDK5) in AD (Fig. 7a).
RNA sequencing data from the GTEx database (GTEx
Consortium, 2015) suggests that GSK3β and CDK5 are
highly expressed in brain tissue. Accumulating studies
suggested that inhibition of GSK3β and CDK5 activity is
a potential therapeutic strategy for AD [83].
We next examined pioglitazone’s mechanism-ofaction using human microglia HMC3 cells. First, to
assess the potential cell cytotoxicity, HMC3 cells were
treated with pioglitazone at various concentrations

(0.03 μM to 100 μM) for 48 h, and cell viability was
determined by MTT method. As presented in Fig. 7b,
pioglitazone at 0.03 μM to 10 μM did not affect cell
viability, revealing low toxicity in human cells. Thus,
these optimized concentrations of pioglitazone (≤ 10
μM) were used in subsequent experiments. As shown
in Fig. 7c, phosphorylation of GSK3β and CDK5 were
significantly increased after LPS treatment (1 μg/mL
for 30 min) in HMC3 cells. Pre-treating with pioglitazone significantly reduced phosphorylated GSK3β and
CDK5 in a dose-dependent manner (Fig. 7d,e and S4).
Altogether, these data suggest that pioglitazone may
offer potential benefits for patients with AD by reducing activation of GSK3β and CDK5. However, further mechanistic observations using patient-derived
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Fig. 6 Hazard ratios and 95% confidence interval (CI) for six cohort studies. Six cohorts include the following: (i) pioglitazone (n = 101,650) vs.
matched control population (n = 402,184), (ii) pioglitazone vs. glipizide (a diabetes drug, n = 191,656); (iii) febuxostat (n = 24,218) vs. control (n =
95,192), (iv) atenolol (n = 366,277) vs. control (n = 1,449,815); (v) nadolol (n = 19,253) vs. control (n = 76,136); and (vi) sotalol (n = 43,819) vs. control
(n = 172,375). For each comparison, we estimated the propensity score for confounding factor (Table 2) adjustment as described in “Material and
methods”

microglia cells or disease-relevant cell lines are
warranted.

Discussion
AD risk involves a complex polygenic and pleiotropic
genetic architecture [1]. The AD genetics altered the
molecular interactions of cellular pathways, which are
represented through the organized structure of molecular networks (i.e., gene regulatory networks) or gene coexpression modules [84, 85]. Traditional reductionist
paradigms overlook the inherent complexity of human
disease and often led to treatments that are inadequate
or have adverse effects [86]. Understanding AD from
the point-of-view of how cellular systems and molecular interactome perturbations underlie the disease is the
essence of network medicine [8]. Based on this hypothesis, we have proposed an artificial intelligence framework for AD drug repurposing, which integrates genetic
findings, multi-omics data, drug-target networks, and the
human protein–protein interactome, along with largescale population-based validation and in vitro mechanistic observations in human microglia cells (see “Material
and methods”).
In total, we identified 103 ARGs by utilizing our
recently developed Bayesian model selection method
[17]. Functional genomics enrichment analysis shows
that ARGs harbor more gene regulatory elements in the
human genome. Both transcriptomics and proteomics
data analyses imply that ARGs are more likely to be differentially expressed in human AD brain and multiple
AD transgenic mouse models. The marginal difference
of fold change (Fig. 2) may be explained by large number of cell subpopulations and low abundance of RNA
expression at single-cell/nucleus levels during differential

expression analysis. These comprehensive observations
suggest that ARGs potentially capture pathobiological
pathways of AD (Fig. 3). Importantly, drug-target network analysis shows a 4-fold higher druggability compared to the known drug targets in the human genome.
A previous study showed that few products (proteins) of
GWAS-derived closest genes could be applied for therapeutic discovery [71].
To compare the performance between the nearest
genes to the risk loci using traditional approach and
ARGs derived from our Bayesian model, we assembled
108 nearest genes (Table S1) to the GWAS loci data we
used (see Supplementary Methods). Unlike to 103 ARGs
(Fig. 2a), 108 GWAS-derived closest genes were randomly distributed in the human interactome network
(7/96, P = 0.217, permutation test, Table S12). In addition, among 25 candidate drugs (with known AD evidence) identified by ARGs, only 2 drugs (hydralazine
and deferoxamine) exerted significant network proximity score with AD (Table S11) based on the 108 nearest genes. None of three positive drugs (pioglitazone [z
= − 1.64], febuxostat [z = − 1.6], and atenolol [z = −
1.16]) in Fig. 5 show significant network proximity score
with the 108 nearest genes. Altogether, these observations implied poor performance of GWAS-derived closest genes as candidate targets for therapeutic discovery,
consistent with previous studies [17, 87]. Several factors
may account for this. First, the reported significant loci
occupy only a small proportion of heritability and provide limited information about underlying AD biology
[88]. Second, many genome-wide significant loci lie in
noncoding regions, and genes closest to index SNPs may
not represent causal genes of AD [89]. Thus, systematic
identification of likely causal genes from GWAS findings
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Fig. 7 Experimental validation of pioglitazone’s proposed mechanism-of-action in Alzheimer’s disease (AD). a Network analysis highlighting the
inferred mechanism-of-action for pioglitazone in AD. The potential molecular mechanisms of pioglitazone were inferred through integration
of known drug targets and predicted AD risk or AD seed genes into brain-specific co-expressed protein–protein interactome network (see
“Material and methods”). The green shadow emphasizes the two key proteins (GSK3B and CDK5) related to drug’s mechanism-of-action. Node size
indicates the protein-coding gene expression level in brain compared with other 31 tissues from GTEx database (GTEx V8 release, 2020). Larger
size highlighting the high expression level in brain compared with other tissues. We excluded the literature-derived protein–protein interactions.
b Effects of pioglitazone on the cell viability of HMC3 cells. HMC3 cells were treated with indicated concentrations of pioglitazone for 48 h and
cell viability was determined using MTT. Data are represented as mean ± SEM (n = 3) and each experiment was performed at least three times
in duplicate. c Effects of pioglitazone on LPS-induced activation of GSK3β (d) and CDK5 (e) in human microglia HMC3 cells. HMC3 cells were
pre-treated with pioglitazone and followed LPS treatment (1 μg/mL, 30 min). The total cell lysates were collected and subjected to Western blot
analysis. Quantification data represent mean ± sd. of two independent experiments

using in silico multi-omics approaches is a crucial step
for understanding AD pathobiology and offers potential
candidate targets for new therapeutic development as
presented in this study.
Network-based drug repurposing from ARG findings prioritize 4 repurposable drug candidates for AD,
including pioglitazone (NCT02913664), carvedilol
(NCT01354444), febuxostat, and fluticasone. Carvedilol,
an FDA-approved drug for hypertension that blocks the
beta adrenergic receptor, significantly attenuates brain
oligomeric β-amyloid level and cognitive deterioration in

two independent AD mice models [90]. Fluticasone is an
approved glucocorticoid receptor agonist for treatment
of asthma, and recent studies showed that long-term use
of fluticasone reduces incidence of developing AD [18,
77]. A propensity-matched analysis has suggested that a
daily dose of 40 mg febuxostat is associated with reduced
likelihood of dementia in older adults [79]. Nevertheless, whether febuxostat reduces the risk of AD dementia
remains unknown. Combining network-based prediction
and patient data observation, we found that febuxostat
is significantly associated with a decreased risk of AD
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(Figs. 5 and 6). In addition, epidemiological studies have
shown that hypertension is a risk factor for AD-related
dementia; yet, there is some dispute as to whether antihypertensive drugs reduce the risk of AD [91, 92]. Among
three adrenergic beta blocker-based antihypertensive
drugs (atenolol, nadolol, and sotalol), atenolol is associated with reduced risk of AD, while nadolol and sotalol
are not (Figs. 5 and 6). Since there are lack of strong preclinical or clinical evidence to support the relationship
between atenolol and AD, we excluded atenolol in our
follow-up studies. However, future studies to confirm
potential beneficial effects of antihypertensive drugs in
reducing AD risk are needed.
Pioglitazone, a U.S. FDA-approved anti-T2D drug,
was reported to restore energy metabolism and
reduce Aβ levels in the brain of APP/PS1 mice [93].
A previous clinical study has shown that pioglitazone
improves cognition and regional cerebral blood flow
in patients with mild AD accompanied with T2D [81].
In this study, by combining network-based prediction
and population-based validation, we found that pioglitazone potentially reduced risk of AD in large-scale
patient database (Figs. 5 and 6). Under active drug
user design framework [15], we chose a comparator
drug having the similar indication with the target drug
pioglitazone. As pioglitazone was approved for antidiabetes, and we therefore chose glipizide as a comparator drug. New active drug user design analysis further
support that pioglitazone is associated with a reduced
risk of AD in comparison to glipizide. In addition,
in vitro mechanistic observations (Fig. 7) reveal that
pioglitazone significantly downregulates expression of
CDK5 and GSK3β in human microglia cells, mechanistically supporting network and population-based
findings. However, a phase II study (NCT00982202)
shows no statistically significant differences between
controls and patients with mild to moderate AD for
pioglitazone [80]. One possible explanation is that
pioglitazone reduces risk of AD only in patients with
pre-existing diabetes or that pioglitazone may have
its effects before symptoms occur but not in more
advanced patients. Thus, our findings suggest that
larger clinical trials and additional mechanistic studies may be necessary to clarify pioglitazone’s action in
AD prevention in both a broad population and a welldefined subpopulation.
Our network methodology presented here has several
strengths. First, it contributes to identification of highconfidence likely causal genes, followed by multi-omics
data validation, network-based drug repurposing investigation, large-scale patient data analysis, and in vitro
mechanistic observation in human microglial cells.
This work illustrates translation of GWAS findings to
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pathobiology and therapeutic development in AD. Second, our proposed network proximity approach outperform other network approaches, such as weighted gene
co-expression network analysis (WGCNA) in which it
infers gene co-expression networks from gene/protein
expression profiles using network community detection
theory [94]. Multiple studies have demonstrated high
false positive rate of the gene/protein co-expression
networks compared to the physical protein–protein
interaction network [95, 96]. Third, the large patientlevel longitudinal data ensures that our analyses integrate real-world patient evidence to test the drug’s
efficiency in AD risk reduction.
Limitations

Potential weaknesses of this work should be acknowledged. First, as genetic variants from GWAS that influence human disease traits are far from complete, a
relative loose threshold (1 × 10−5) rather than genomewide significant threshold (5 × 10−8) is adopted, which
may affect the accuracy of identification of ARGs. Second, we only integrated SNPs associated with AD from
large-scale GWAS studies conducted between 2007 and
2019. Since several recent GWAS studies have been conducted [97, 98], we may identify new AD-associated risk
genes via integration of the latest novel GWAS loci for
AD in the future. Third, incompleteness of human protein–protein interactome network data and potential
literature bias may influence performance of our methodology as discussed in a recent study [99]. Since the
likely causal genes were predicted based on SNPs identified from GWAS that are primarily centered on the
variants in the noncoding regions, some AD genes or
proteins harboring protein-coding variants may not be
covered in this study. Integration of large-scale wholegenome/exome sequencing from the Alzheimer’s Disease
Sequencing Project (ADSP; https://www.niagads.org/
adsp/content/home) may offer novel risk genes for AD.
Fourth, detailed clinical information is missing for health
insurance claims data regardless of high-dimensional
covariate adjustment. This limits our ability to test the
effects of pioglitazone on subpopulation of AD patients
such as those with mild AD. Longitudinal analyses were
conducted in populations without biological confirmation of AD by biomarkers, such as lack of cerebrospinal
fluid information (i.e., levels of Aβ and Tau), which may
affect the results of pharmacoepidemiologic analyses. In
addition, although our dataset contains a geographically
diverse population of commercially insured Americans
seniors, the results are not representative of individuals
who are not commercially insured or uninsured. The phenotyping algorithms may not capture all AD cases. Thus,
this approach may need to be re-applied on a regular
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iterative basis as datasets are expanded, in order to offer
maximum utility. Furthermore, clinical data heterogeneity from real-world patients and other confounding
factors may lead to potential false positive rate in population-based drug outcome analysis. Finally, all novel ARGs
need to be validated experimentally (including both
in vitro and in vivo) and clinical benefits of drugs must be
tested in AD randomized clinical trials in the future.

NIH-NHGRI U01HG009086 (Q.W., R.C., and B.L.). This work was supported in
part by Brockman Foundation (A.A.P); AHA/Allen Initiative, Grant/Award Num‑
ber: 19PABH134580006 (A.A.P.).

Conclusion
In summary, this study presents a network-based artificial intelligence methodology to translate GWAS
findings to emerging therapeutic discovery by incorporating multi-omics, drug-target network, and the
human protein–protein interactome, along with largescale population-based and in vitro mechanistic observation. This study shows the strong proof-of-concept
application of high-confidence risk gene identification
from human genetic and multi-omics findings to identifying treatments that can be repurposed for AD and has
identified pioglitazone as a potential new treatment for
AD using artificial intelligence approaches. In this way,
we can minimize the translational gap between genetic
findings and clinical outcomes, which is a significant
problem in current AD therapeutic development. From
a translational perspective, if broadly applied, the artificial intelligence-based tools developed here could help
develop novel efficacious treatment strategies for other
human complex diseases.
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